Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reinforcing strong pharmaceutical demand for next-generation antibody-drug conjugate (“ADC”) technologies. The latest transaction adds to a growing list of multibillion-dollar ADC and T-cell engager (“TCE”) deals, highlighting continued strategic investment in differentiated antibody platforms.
VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology’s most active partnering environments, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody therapeutics. The latest example came this week as Novartis agreed to acquire Myricx Bio for $1.1 billion upfront, plus up to $400 million in milestone payments, to gain access to the company’s novel N-myristoyltransferase inhibitor (“NMTi”) payload platform and two lead ADC programs. The acquisition reflects continued industry demand for innovative antibody technologies capable of addressing limitations of existing cancer therapies.
The Novartis transaction follows a series of major antibody therapeutics deals, including Jazz Pharmaceuticals’ collaboration with AbCellera, Gilead Sciences’ acquisition of Tubulis and multiple multibillion-dollar ADC licensing agreements. VERAXA is advancing proprietary antibody therapeutics spanning both ADCs and TCEs through its patented BiTAC platform, positioning the company within two therapeutic categories that continue to attract significant pharmaceutical investment, strategic collaborations and acquisition activity.
For investors, the Novartis-Myricx deal signals that the antibody therapeutics market remains a hotbed of M&A activity, with large pharma willing to pay substantial premiums for innovative platforms. This environment creates potential opportunities for companies like VERAXA, which is developing next-generation antibody-based therapeutics using its BiTAC technology. The company’s pipeline includes bispecific T cell engagers and bispecific ADCs, formats that have drawn increasing interest from larger drugmakers seeking to bolster their oncology portfolios.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company’s BiTAC platform is designed to overcome limitations of existing antibody therapies by enabling more potent and targeted killing of cancer cells.
The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.
